Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessExact Sciences Corporation (NASDAQ:EXAS) Shows Promising Growth in Cancer Diagnostics

Exact Sciences Corporation (NASDAQ:EXAS) Shows Promising Growth in Cancer Diagnostics

Add to Favorite
Added to Favorite


Analysts’ confidence in Exact Sciences is growing, with a significant increase in the consensus price target to $95, suggesting a potential 34.3% increase in stock value.
Jefferies analyst Brandon Couillard sets an ambitious price target of $140 for EXAS, based on the company’s potential to surpass quarterly earnings estimates.
Exact Sciences’ strategic focus on enhancing diagnostic tests and partnerships is expected to boost Precision Oncology revenues, contributing to a positive third-quarter earnings performance.

Exact Sciences Corporation (NASDAQ:EXAS) is a leader in cancer screening and diagnostic tests, focusing on non-invasive methods like the Cologuard test for colorectal cancer. The company is gaining attention for its innovative approach to cancer diagnostics, which sets it apart from competitors in the medical sector.

Over the past year, the consensus price target for EXAS stock has shown a positive trend. A year ago, the average price target was $79.73, which increased to $82.83 in the last quarter. More recently, it has risen significantly to $95. This upward trend suggests growing confidence among analysts in the company’s potential, as highlighted by the positive outlook from Wall Street analysts.

Investors are advised to consider EXAS as a promising opportunity. Analyst Brandon Couillard from Jefferies has set a price target of $140, indicating potential for significant growth. This recommendation is based on the expectation that EXAS will surpass quarterly earnings estimates, as suggested by the Zacks Earnings ESP. The stock’s recent 7.5% increase since its last earnings report further supports this optimistic view.

Exact Sciences’ focus on enhancing existing products and developing new diagnostic tests, along with strategic partnerships, may be contributing to the positive outlook. The company is expected to see a boost in its Precision Oncology revenues, driven by increased laboratory service revenues from its global Oncotype DX and therapy selection tests. This focus on screening sales could play a significant role in its third-quarter earnings performance.

The company’s recent upgrade to a Zacks Rank #1 (Strong Buy) indicates a positive outlook on its earnings prospects. This upgrade, along with the consensus price target suggesting a potential 34.3% increase in the stock’s value, reflects growing optimism about Exact Sciences’ future performance. The market is closely watching to see if the company can maintain its momentum and reach the ambitious price target set by analysts.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Revitty Incorporated’s Q3 Earnings Overview

Earnings per Share (EPS) of $0.935 missed the expected...

Century Casinos, Inc. (NASDAQ:CNTY) Q3 Earnings Overview

Earnings per Share (EPS) fell short of estimates, reporting...

Hologic, Inc. (NASDAQ:HOLX) Q4 2024 Earnings Overview

Earnings Per Share (EPS) matched the estimated EPS of...